Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allon starts another trial of neuroprotective drug davunetide

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Patient enrollment has started in an additional clinical trial for Allon's lead neuroprotective agent davunetide, the firm announced Jan. 28, with the aim of broadening the demonstrated safety range and pharmacokinetic profile. Davunetide, which has been considered a top licensing opportunity in the neuroscience field, is slated to begin Phase II later in 2010 for frontotemporal dementias, "a group of rapidly progressive and fatal degenerative brain diseases often misdiagnosed as Parkinson's or Alzheimer's disease," the company explains. FDA has granted orphan status for treatment of progressive supranuclear palsy, a type of FTD. Allon has already demonstrated efficacy and "an excellent safety profile" in Phase II trials in patients with amnestic mild cognitive impairment, a precursor to Alzheimer's disease, and in patients with cognitive impairment associated with schizophrenia
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS004352

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel